Peptide Immunotherapy Enhancing Adaptive Immune Response

The patent combines a peptide with a specific amino acid sequence that binds to MHC molecules with antibodies against immune checkpoint proteins. This combination therapy merges two distinct mechanisms: peptide-MHC complex presentation to activate T cells, and checkpoint blockade to remove inhibitory signals. The synergistic effect overcomes immune suppression more effectively than either approach alone, addressing the insufficiency of current immunotherapy in activating adequate adaptive immune responses against cancer.

The peptide component acts as an intermediary that facilitates robust antigen presentation by forming stable complexes with MHC molecules. This enhanced antigen presentation serves as a reliable mediator that activates stronger and more sustained T cell responses, which are necessary to overcome tumor immune suppression and evasion mechanisms, thereby improving both tumor control and reliability of immune activation.

The patent utilizes parameter changes by modifying the peptide's amino acid sequence to optimize its binding affinity to MHC molecules and its ability to stimulate immune responses. By carefully selecting and adjusting specific amino acid residues, the composition achieves high levels of anti-cancer cytokine production while maintaining a relatively simple two-component structure (peptide plus checkpoint antibody), thus increasing cytokine quantity without proportionally increasing compositional complexity.